|
|
|
[unknown placeholder $cat.num$] Last Updated: Sep 7, 2009 - 7:33:33 PM |
Public Companies
:
Healthcare/BioTech
MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering Pharma
MARTINSRIED, GERMANY and MUNICH, GERMANY -- (Marketwire) -- 09/08/09 --
Sep 8, 2009 - 1:36:08 AM
Public Companies
:
Healthcare/BioTech
OctoPlus wins expansion of drug delivery evaluation contract with existing client
LEIDEN, NETHERLANDS -- (Marketwire) -- 09/08/09 --
Sep 8, 2009 - 1:36:04 AM
Public Companies
:
Healthcare/BioTech
Transaction in Own Shares
BAGSVÆRD, DENMARK -- (Marketwire) -- 09/07/09 -- Novo Nordisk A/S - Sharerepurchase programme
Sep 7, 2009 - 7:36:01 AM
Public Companies
:
Healthcare/BioTech
IntelGenx Technologies Corp. Completes Additional Private Placement
SAINT LAURENT, QUEBEC -- (Marketwire) -- 09/04/09 -- IntelGenx Technologies Corp. (the "Company") (TSX VENTURE: IGX)(OTCBB: IGXT) announced today that it has completed the sale of 250,000 units ("Units") at a price of Cdn $0.41 per unit for gross proceeds of Cdn $102,500.00 (the "Offering"). Each Unit comprises one common share ("Common Share") of the Company and one common share purchase warrant ("Warrant"). Each Warrant entitles the holder thereof to purchase one Common Share at a price of US $0.80 ("Exercise Price") until September 3, 2012. The Company issued and sold approximately 10.5 million Special Warrants under its previously announced private placement offering for Cdn $0.40 per Special Warrant for gross proceeds of approximately Cdn $4.2 million on July 13, 2009.
Sep 4, 2009 - 3:36:01 PM
Public Companies
:
Healthcare/BioTech
SciClone Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
FOSTER CITY, CA -- (Marketwire) -- 09/04/09 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at the Rodman & Renshaw AnnualGlobal Investment Conference in New York City. Friedhelm Blobel, Ph.D.,SciClone's President and Chief Executive Officer, will present a corporateoverview and business update on Thursday, September 10, 2009 at 10:50 amET.
Sep 4, 2009 - 3:36:01 PM
Public Companies
:
Healthcare/BioTech
Facet Biotech Confirms Receipt of Biogen Idec Letter
REDWOOD CITY, CA -- (Marketwire) -- 09/04/09 -- Facet Biotech Corporation (NASDAQ: FACT)confirms that it is in receipt of Biogen Idec Inc.'s (NASDAQ: BIIB) letterdated September 4, 2009 offering $14.50 per share for all of theoutstanding shares of Facet.
Sep 4, 2009 - 2:36:01 PM
Public Companies
:
Healthcare/BioTech
Edwards Lifesciences to Present at the UBS Fourth Annual Best of Americas Conference
IRVINE, CA -- (Marketwire) -- 09/04/09 -- Edwards Lifesciences Corporation (NYSE: EW), aworld leader in products and technologies to treat advanced cardiovasculardisease, is scheduled to participate in the UBS Fourth Annual Best ofAmericas Conference at UBS' offices in London, England on Friday, September11, 2009.
Sep 4, 2009 - 1:36:01 PM
Public Companies
:
Healthcare/BioTech
ChromoCure, Inc. Announces Co-Development Agreement for New CS300 Scanner Series in Preparation for Nationwide Distribution
RENO, NV -- (Marketwire) -- 09/04/09 -- ChromoCure, Inc. (PINKSHEETS: KKUR) announcedtoday it executed a Technology Co-Development Agreement with its primarycell preparation and application technology supplier. The co-developmentagreement calls for the joint-development of a fully integrated chromosomalscanner system for nation-wide distribution to pathology and related cancerdetection labs.
Sep 4, 2009 - 11:36:38 AM
Public Companies
:
Healthcare/BioTech
Results Obtained at Sunnybrook With ART's Softscan Breast Imaging System Presented at IEEE International Conference
MONTREAL, CANADA -- (Marketwire) -- 09/04/09 -- ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce that Dr. Gregory Czarnota, MD, PhD, Radiation Oncologist at Odette Cancer Centre, Sunnybrook Health Sciences Centre, will be presenting SoftScan® clinical results from a breast cancer treatment monitoring study, at the IEEE Engineering in Medicine and Biology Society 31st Annual International Conference in Minneapolis, Minn. The study to determine the efficacy of the SoftScan system in monitoring response to treatment of breast cancer, particularly neoadjuvant therapies, was conducted at the Sunnybrook Health Sciences Centre, among North America's most important cancer centres, with Dr. Czarnota as the principal investigator.
Sep 4, 2009 - 10:36:01 AM
Public Companies
:
Healthcare/BioTech
Molecular Insight Pharmaceuticals, Inc. to Present at Rodman and Renshaw 11th Annual Healthcare Conference
CAMBRIDGE, MA -- (Marketwire) -- 09/04/09 -- Molecular InsightPharmaceuticals, Inc. (NASDAQ: MIPI) will make a presentation at theRodman and Renshaw 11th Annual Healthcare Conference on September 10, 2009at 2 PM, Eastern Daylight Time. Daniel L. Peters, President and ChiefExecutive Officer, will present an overview of the Company and its pipelineof targeted therapeutic and molecular imaging radiopharmaceuticals. Thepresentation will take place in the Fahnestock Salon, on the fifth floor ofthe New York Palace Hotel in New York, New York.
Sep 4, 2009 - 9:36:01 AM
Public Companies
:
Healthcare/BioTech
Unilife Announces Proposed Redomiciliation of the Unilife Group to the United States and Proposed Listing on NASDAQ
LEWISBERRY, PA -- (Marketwire) -- 09/04/09 -- Unilife Medical Solutions Limited (UnilifeAustralia or the Company) (ASX: UNI) (PINKSHEETS: UNIFF) today announcedthat it entered into a Merger Implementation Agreement with UnilifeCorporation (Unilife USA), a wholly owned subsidiary of Unilife Australia.The purpose of the Merger Implementation Agreement is to facilitate theproposed redomiciliation of the Unilife group to the United States ofAmerica (Proposed Transaction).
Sep 4, 2009 - 8:36:01 AM
Public Companies
:
Healthcare/BioTech
Edmonton-Based COLD-FX(R) Provides Its Flu Fighter to Eight Thousand Edmonton Kindergarden, Elementary and Secondary School Teachers as the School Year Begins
EDMONTON, ALBERTA -- (Marketwire) -- 09/04/09 -- The maker of COLD-FX® - Afexa Life Sciences Inc. - today announced plans to provide 8,000 kindergarten, elementary and secondary school teachers in Edmonton with COLD-FX to protect them during the upcoming flu season.
Sep 4, 2009 - 7:36:01 AM
Public Companies
:
Healthcare/BioTech
The Medicines Company Receives Paragraph IV Notifications
PARSIPPANY, NJ -- (Marketwire) -- 09/04/09 -- The Medicines Company (NASDAQ: MDCO) todayannounced that it has received Paragraph IV Certification notice lettersfrom Teva Parenteral Medicines, Inc. (TPM) and Pliva Hrvatska, d.o.o.(Pliva) notifying the Company that TPM and Pliva have submitted AbbreviatedNew Drug Applications (ANDAs) to the U.S. Food and Drug Administration(FDA) for approval to market generic versions of Angiomax. TheCertification notice letters relate to U.S. patent No. 7,582,727, therecently issued product patent.
Sep 4, 2009 - 6:36:01 AM
Public Companies
:
Healthcare/BioTech
Biotie Therapies to present at Rodman & Renshaw Annual Healthcare Conference
TURKU, FINLAND -- (Marketwire) -- 09/04/09 --
Sep 4, 2009 - 3:36:02 AM
Public Companies
:
Healthcare/BioTech
Active Biotech to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
LUND, SWEDEN -- (Marketwire) -- 09/04/09 -- Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present at the Rodman & Renshaw 11th AnnualHealthcare Conference on Friday, September 11 at the New York PalaceHotel in New York City, US. During the presentation, an updateregarding Active Biotech's development programs will be provided.
Sep 4, 2009 - 1:36:01 AM
Public Companies
:
Healthcare/BioTech
Oncology Surgeons Expedite Breast Cancer Treatment With Use of Oncotype DX(R) at Surgery or Biopsy
REDWOOD CITY, CA -- (Marketwire) -- 09/03/09 -- In an effort to provide breast cancer patients with prompt, critical information abouttreatment options for use at their first visit with the medical oncologist,a number of leading U.S. surgeons request GenomicHealth's Oncotype DX molecular test at the time of surgery or biopsy.
Sep 3, 2009 - 4:36:01 PM
Public Companies
:
Healthcare/BioTech
ProMetic to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference
MONTREAL, QUEBEC -- (Marketwire) -- 09/03/09 -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") today announced that Mr. Pierre Laurin, President and Chief Executive Officer, will present at Rodman & Renshaw's Eleventh Annual Healthcare Conference. ProMetic's presentation is scheduled for 11:40 (EDT) on Wednesday, September 9, 2009. The conference is being held from September 9 - 11, 2009, at the New York Palace Hotel in New York. Details regarding the conference can be obtained at http://www.rodmanrenshaw.com/conferences.
Sep 3, 2009 - 12:36:01 PM
Public Companies
:
Healthcare/BioTech
AspenBio Pharma to Present at the Rodman & Renshaw Annual Global Investment Conference
CASTLE ROCK, CO -- (Marketwire) -- 09/03/09 -- AspenBio Pharma, Inc. (NASDAQ: APPY), anemerging bio-science company dedicated to the development of noveldiagnostics and drugs for humans and animals, has been invited to presentat the Rodman & Renshaw Annual Global Investment Conference to be held atthe New York Palace Hotel on September 9-11, 2009.
Sep 3, 2009 - 11:36:01 AM
Public Companies
:
Healthcare/BioTech
Real American Brands, Inc. Announces Medical Transport Division
NEW YORK, NY -- (Marketwire) -- 09/03/09 -- Real American Brands, Inc. (PINKSHEETS: RLAB)announced today that the company has approved plans to pursue and operatean emergency and non-emergency health services transportation division, tobe developed in close consultation with transport and medical personnel whohave broad experience in the field.
Sep 3, 2009 - 11:36:01 AM
Public Companies
:
Healthcare/BioTech
Alzheimer's Therapeutics Reviewed by NeuroInvestment
CARDIFF, CA -- (Marketwire) -- 09/03/09 -- NI Research has released the September issue ofNeuroInvestment, featuring a review of Alzheimer's therapeutics, includinga critical look at the pharma industry's premature rush to closure: "Giventhe lack of congruence between the doctrine and the data, one might wellconclude that 'everything we know about Alzheimer's is wrong, includingthat.' There is precious little clinical evidence to show that we are onthe right track in Alzheimer's."
Sep 3, 2009 - 11:36:01 AM
Public Companies
:
Healthcare/BioTech
ChromoCure, Inc. Announces Technology and Intellectual Property Assets Acquisition Adding $1,500,000 to Assets and Equity
RENO, NV -- (Marketwire) -- 09/03/09 -- ChromoCure, Inc. (PINKSHEETS: KKUR) announcedtoday it executed a Technology Purchase and Transfer Agreement for$1,500,000, payable in Preferred Stock, wherein the Company receives fulltitle and transfer of all rights, trademarks, intellectual property,protocols, patent disclosures, chromosomal scanner equipment, allproprietary analysis algorithms, mathematical analysis procedures, priortesting data with cancer clinics, cell preparation procedures, and all newhardware designs currently in development related to cancer detection andchromosomal scanning, enumeration, and analysis.
Sep 3, 2009 - 11:36:01 AM
Public Companies
:
Healthcare/BioTech
AspenBio Pharma to Present at the Annual Baird Healthcare Conference
CASTLE ROCK, CO -- (Marketwire) -- 09/03/09 -- AspenBio Pharma, Inc. (NASDAQ: APPY), anemerging bio-science company dedicated to the development of noveldiagnostics and drugs for humans and animals, has been invited to presentat the Annual Baird Healthcare Conference at the Four Seasons Hotel in NewYork City on Thursday, September 10, 2009.
Sep 3, 2009 - 11:36:01 AM
Public Companies
:
Healthcare/BioTech
MDRNA, Inc. to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
BOTHELL, WA -- (Marketwire) -- 09/03/09 -- MDRNA, Inc. (NASDAQ: MRNA) announced today thatit will present at the Rodman & Renshaw 11th Annual Healthcare Conferenceon Thursday, September 10, 2009, at 9:10 a.m. Eastern Time (6:10 a.m.Pacific Time) at the New York Palace Hotel in New York City. J. MichaelFrench, MDRNA's President and Chief Executive Officer, will present acorporate overview and business update. Prior to the corporatepresentation, Mr. French will represent MDRNA on the RNAi TherapeuticsPanel moderated by Simos Simeonidis, Ph.D., Director & Senior BiotechnologyAnalyst at Rodman & Renshaw.
Sep 3, 2009 - 10:36:01 AM
Public Companies
:
Healthcare/BioTech
SPi Healthcare Appoints Mr. Steve Mandell as Vice President of Business Development
NASHVILLE, TN -- (Marketwire) -- 09/03/09 -- SPi Healthcare, a leading provider of medicaltranscription services, announced today the appointment of Mr. SteveMandell as the Vice President of Business Development.
Sep 3, 2009 - 8:36:01 AM
Public Companies
:
Healthcare/BioTech
Pyng Medical MAT(R) Tourniquet Featured in Wired Magazine's Top 10 Designs for Good
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 09/03/09 -- Pyng Medical Corp.'s (the "Company") (TSX VENTURE: PYT) MAT® Tourniquet is being featured in the October edition of Wired UK Magazine as one of the "Top 10 Designs for Good."
Sep 3, 2009 - 8:36:01 AM
Public Companies
:
Healthcare/BioTech
China Aoxing Pharmaceutical Company Announces Submission of NDA of Its Leading Narcotic Drug for the Treatment of Acute Moderate to Severe Cough
NEW YORK, NY -- (Marketwire) -- 09/03/09 -- China Aoxing Pharmaceutical Company, Inc.(OTCBB: CAXG) ("China Aoxing"), a pharmaceutical company specializing inresearch, development, manufacturing and marketing of narcotic andpain-management products, today announced that it has submitted a new drugapplication (NDA) to the China State Food and Drug Administration (SFDA)for its Codeine Phosphate, a compound oral solution for the treatment ofacute moderate to severe cough.
Sep 3, 2009 - 7:36:01 AM
Public Companies
:
Healthcare/BioTech
Thomson Reuters and BioCentury Showcase NewsMakers in the Biotech Industry
NEW YORK, NY -- (Marketwire) -- 09/03/09 -- Thomson Reuters and BioCentury are pleased to announcethe presenting companies in their 16th Annual NewsMakers in the BiotechIndustry conference. The conference takes place on September 16th atNew York City's Millennium Broadway Hotel and Conference Center. The event-- the longest running independent investment meeting dedicated to thebiopharma space -- remains the one turf neutral conference that bringstogether the Wall Street financial community to kick off the fallinvestment season.
Sep 3, 2009 - 7:36:01 AM
Public Companies
:
Healthcare/BioTech
Medical Nutrition USA to Announce Fiscal 2010 Second Quarter Results, Thursday, September 10
ENGLEWOOD, NJ -- (Marketwire) -- 09/03/09 -- Medical Nutrition USA, Inc. (NASDAQ: MDNU)announced today it will issue its financial results for the fiscal secondquarter ended July 31, 2009, before the market opens on Thursday, Sept. 10.Management will host a webcast and conference call that same day at 11:00a.m. EDT to discuss these results, recent activities, corporate news andCompany strategy.
Sep 3, 2009 - 7:36:01 AM
Public Companies
:
Healthcare/BioTech
Macada Holding, Inc. Announces It Has Hired a Top SEC Attorney and Auditors
FT. LAUDERDALE, FL -- (Marketwire) -- 09/03/09 -- Macada Holding, Inc. (PINKSHEETS: MCDA)announces the company has hired a top SEC attorney, Mark Perry, andauditors Bagell, Joseph and Levine, LLC, one the countries top 35 auditingfirms, to complete all documentation to close existing deals and begin thecompany's audit. This shall complete all filings and give the ability tobecome a reporting company. Once completed, this ensures the realization ofthe company strength and ability to implement its new plan of actions andmergers and acquisitions.
Sep 3, 2009 - 7:36:01 AM
Public Companies
:
Healthcare/BioTech
Given Imaging to Present at Upcoming Investor Conferences
YOQNEAM, ISRAEL -- (Marketwire) -- 09/03/09 -- Given Imaging (NASDAQ: GIVN) todayannounced that company management will present at upcoming investorconferences in September.
Sep 3, 2009 - 7:36:01 AM
Public Companies
:
Healthcare/BioTech
Antisoma to present at the Rodman & Renshaw Healthcare Conference in New York
LONDON -- (Marketwire) -- 09/03/09 --
Sep 3, 2009 - 6:36:01 AM
Public Companies
:
Healthcare/BioTech
Pharming submits marketing authorisation application for Rhucin(R) to the EMEA
LEIDEN, NETHERLANDS -- (Marketwire) -- 09/03/09 -- Biotech company PharmingGroup NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) todayannounced that it has submitted the Marketing AuthorizationApplication (MAA) for Rhucin for the treatment of acute attacks ofHereditary Angioedema (HAE) to the European Medicines Agency (EMEA).
Sep 3, 2009 - 1:36:01 AM
Public Companies
:
Healthcare/BioTech
American Dental Partners to Present at the Robert W. Baird & Co. 2009 Health Care Conference
WAKEFIELD, MA -- (Marketwire) -- 09/02/09 -- American Dental Partners, Inc. (NASDAQ: ADPI)announced today that Breht T. Feigh, Executive Vice President, ChiefFinancial Officer and Treasurer, will present at the Robert W. Baird & Co.2009 Health Care Conference in New York City on Wednesday, September 9,2009, at 3:45 p.m. EDT.
Sep 2, 2009 - 5:36:01 PM
Public Companies
:
Healthcare/BioTech
XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
MALVERN, PA -- (Marketwire) -- 09/02/09 -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL),a specialty biopharmaceutical company, today announced that The New EnglandJournal of Medicine (NEJM) has published in its September 3rd edition, theCompany's pivotal CORD I Phase III clinical trial of XIAFLEX(TM)(collagenase clostridium histolyticum) a novel, first-in-class, biologicfor the nonsurgical treatment of Dupuytren's contracture. The CORD I studyis the largest prospective clinical trial ever conducted in the field ofDupuytren's contracture. Treatment with XIAFLEX significantly reduced theangle of contracture for patients with Dupuytren's contracture in boththeir metacarpophalangeal (MP) and proximal interphalangeal (PIP) joints,with clinically meaningful responses in both less severe and more severecontractures.
Sep 2, 2009 - 4:36:01 PM
Public Companies
:
Healthcare/BioTech
Facet Biotech Announces Participation at Upcoming Investor Conferences
REDWOOD CITY, CA -- (Marketwire) -- 09/02/09 -- Facet Biotech Corporation (NASDAQ: FACT)today announced that the company will participate at upcoming investorconferences. These conferences include:
Sep 2, 2009 - 3:36:01 PM
|
|
|
|
